Acadia Pharmaceuticals (ACAD) Long-Term Deferred Tax: 2022-2024
- Acadia Pharmaceuticals' Long-Term Deferred Tax rose 27.94% to $8.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.7 million, marking a year-over-year increase of 27.94%. This contributed to the annual value of $8.7 million for FY2024, which is 27.94% up from last year.
- Per Acadia Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $8.7 million for Q4 2024, which was up 27.94% from $6.8 million recorded in Q4 2023.
- In the past 5 years, Acadia Pharmaceuticals' Long-Term Deferred Tax registered a high of $8.7 million during Q4 2024, and its lowest value of $1.2 million during Q4 2022.
- Over the past 3 years, Acadia Pharmaceuticals' median Long-Term Deferred Tax value was $6.8 million (recorded in 2023), while the average stood at $5.6 million.
- Data for Acadia Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY spiked of 466.67% (in 2023) over the last 5 years.
- Over the past 3 years, Acadia Pharmaceuticals' Long-Term Deferred Tax (Quarterly) stood at $1.2 million in 2022, then skyrocketed by 466.67% to $6.8 million in 2023, then rose by 27.94% to $8.7 million in 2024.
- Its last three reported values are $8.7 million in Q4 2024, $6.8 million for Q4 2023, and $1.2 million during Q4 2022.